Adverse Reactions (3% and Greater than Placebo) in WEGOVY-Treated Pediatric Patients Aged 12 Years and Older with Obesity for Weight Reduction Adverse Reactions in Clinical Trials in Adults with MASH The safety of WEGOVY was evaluated in a randomized, double-blind, placebo-controlled trial (Study 8) that included 1,195 adult patients with MASH, including 800 patients who were exposed to WEGOVY for a median of 95.3 weeks and 395 patients who were exposed to placebo for a median of 83.1 weeks [see Clinical Studies (14.4)]
Kadouh H, Chedid V, Halawi H, Burton DD, Clark MM, Khemani D, et al
The Biden administration plan would have allowed Medicare and Medicaid to cover anti-obesity medications for people with obesity, even if they do not have a cardiovascular disease
Those discontinuing GLP-1 medications rapidly regained weight January 14, 2025 Summary: Despite their benefits, many people stop GLP-1 weight loss drugs, sometimes due to lack of coverage
Key Takeaways: Should Pregnant or Breastfeeding Women Take Glutathione
S., Ryu, H
